文献速递甲状腺疾病

2007至2016年美国商业保险与联邦医疗保险受益人甲状腺激素仿制药与原研药使用趋势

Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

基于2007至2016年大型行政理赔数据库的横断面纵向分析,纳入商业保险、Medicare Advantage和Medicare Part D的成人参保者,评估甲状腺激素仿制药与原研药使用模式。结果显示甲状腺激素药房配药量从8,905,836增至11,613,923,仿制药 dispensing 比例从59.8%升至84.9%,原研药使用在老年人中较少、女性及内分泌科医生处方者中更常见,处方医生专科是最强预测因素。

要点

  • 2007至2016年甲状腺激素仿制药 dispensing 比例由59.8%升至84.9%。
  • 原研药使用在女性、白人及高收入Medicare Advantage和商业保险人群中更常见。
  • 处方医生为内分泌科医生是原研药使用的最强预测因素。

核心结论

  • 2007至2016年间三个全国性保险受益人群体中甲状腺激素原研药使用下降,处方医生专科是最强预测因素。

主要发现

  • 甲状腺激素年度药房配药量从2007年8,905,836增至2016年11,613,923,其中73.6%为仿制左甲状腺素,23.4%为原研左甲状腺素,其余为其他剂型。
  • 仿制甲状腺激素药物 dispensing 比例从2007年59.8%升至2016年84.9%,且在Medicare Advantage和Medicare Part D中持续高于商业保险人群。
  • 三个受益人群体中,原研药使用在老年人中较少,在女性及接受内分泌科医生处方者中更常见;在Medicare Advantage和商业保险人群中,白人及家庭收入更高者原研药使用更常见(P < 0.001)。

临床怎么用

  • 临床处方甲状腺激素时可关注仿制药与原研药的选择模式,尤其内分泌科医生处方与女性患者中原研药使用更常见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Generic drugs account for 9 out of 10 prescriptions dispensed in the United States but for a lower proportion of commonly prescribed thyroid hormone replacement therapies. OBJECTIVE: Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. DESIGN AND SETTING: Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. PATIENTS: Adults with insurance coverage through commercial, Medicare Advantage, and Medicare Part D health plans. MAIN OUTCOME MEASURES: Generic and brand-name thyroid hormone drug use. RESULTS: From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6% of which were for generic levothyroxine, 23.4% for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8% in 2007 to 84.9% in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists and was more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (P < 0.001). CONCLUSIONS: Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. Although certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ross JS, Rohde S, Sangaralingham L, et al. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. J Clin Endocrinol Metab. 2019. PMID: 30690529. doi:10.1210/jc.2018-02197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。